> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Status for Veralox Thrombocytopenia Drug
- URL: https://www.fdaweb.com/orphan-status-for-veralox-thrombocytopenia-drug/
- Published: 2021-01-27T12:00:00.000Z
- Updated: 2026-09-14T16:44:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148539

FDA has granted Veralox Therapeutics an orphan drug designation for VLX-1005 for treating heparin-induced thrombocytopenia (HIT). VLX-1005 is described as a first-in-class and selective small molecule inhibitor 12-Lipoxygenase, a key target within the arachidonic acid pathway. “Preclinical data has demonstrated that VLX-1005 halts immune driven platelet activation and thrombosis thus offering the potential of a lifesaving treatment for patients with HIT,” the company says.